Feedback / Questions
cendakimab (CC-93538) - AbbVie, BMS
BMS-986322 - BMS
https://www.fiercebiotech.com/biotech/bristol-myers-backs-out-dupixent-fight-axing-allergy-asset-despite-phase-3-win
Feb 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next